Middle East And Africa Genetic Testing Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2023 –2030 |
 Taille du marché (année de référence) |
|
 Taille du marché (année de prévision) |
|
 TCAC |
% |
| Principaux acteurs du marché |
Marché des tests génétiques au Moyen-Orient et en Afrique, par type (tests de porteurs, tests de diagnostic, dépistage néonatal, tests prédictifs et présymptomatiques, tests prénatals, autres types), technologie (séquençage de l'ADN (tests basés sur le NGS), réaction en chaîne par polymérase, microarrays, séquençage du génome entier, hybridation in situ en fluorescence (FISH) et autres), maladies (troubles génétiques rares, cancer, fibrose kystique , tests génétiques de la reproduction, tests génétiques de santé et de bien-être, drépanocytose, dystrophie musculaire de Duchenne, thalassémie, maladie de Huntington, syndrome de l'X fragile et autres), utilisateur final (hôpitaux, cliniques, centres de diagnostic, cliniques privées, prestataires de services de laboratoire et laboratoires privés) Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché des tests génétiques au Moyen-Orient et en Afrique
Le marché des tests génétiques au Moyen-Orient et en Afrique est stimulé par des facteurs tels que la forte prévalence des troubles génétiques, les avancées technologiques croissantes sur le marché des tests génétiques, qui augmentent sa demande, ainsi que l'augmentation des investissements dans la recherche et le développement, ce qui conduit à la croissance du marché. Actuellement, les dépenses de santé ont augmenté dans les pays développés et émergents, ce qui devrait créer un avantage concurrentiel pour les fabricants afin de développer de nouveaux marchés de tests génétiques innovants.
Le marché des tests génétiques au Moyen-Orient et en Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2023 à 2030. Data Bridge Market Research analyse que le marché croît avec un TCAC de 13,6 % au cours de la période de prévision de 2023 à 2030 et devrait atteindre 1 374,13 millions USD d'ici 2030.
Le rapport sur le marché des tests génétiques au Moyen-Orient et en Afrique fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Années historiques |
2021 (personnalisable pour 2020-2015) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
By Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive and Presymptomatic Testing, Prenatal Testing, Other Types), Technology (DNA Sequencing (NGS-Based Testing), Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Reproductive Genetic Testing, Health & Wellness Genetic Testing, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, and Other), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories). |
|
Countries Covered |
South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa. |
|
Market Players Covered |
Abbott, 23ANDME, Inc., Danaher, Myriad Genetics, Inc., OCP Medical Centre, L.L.C, Healthchecks360, Bayer AG, BioReference Health, LLC (a subsidiary of OPKO Health, Inc.), FREIBURG MEDICAL LABORATORY MIDDLE EAST (L.L.C.), Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Biocartis, Eurofins Scientific, PerkinElmer Inc., ELITechGroup, F. Hoffmann-La Roche Ltd., Illumina, Inc., QIAGEN, BIO-HELIX, and PacBio among others. |
Market Definition
Genetic testing is a kind of medical test that identifies changes in genes, chromosomes, or proteins. The outcome of a genetic test can confirm or rule out a suspected genetic condition or aid in determining a person's chance of developing or passing on a genetic disorder. Over 77,000 genetic tests are currently in use, and others are being developed.
The increasing innovations and technologies and rising number of players in the market, and novel product launches are also propelling the growth of the Middle East and Africa genetic testing market.
Middle East and Africa Genetic Testing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers/Opportunities
- Growing prevalence of genetic disorders
Genetic disorders may cause such severe health problems which are incompatible with life. In the most severe cases, these conditions may cause a miscarriage of an affected embryo or fetus. The rising prevalence of genetic diseases and birth defects boosts the demand for the genetic testing market.
- As per the article by World Health Organization, genetic disorders and congenital abnormalities: strategies for reducing the burden in the region, 2022, genetic and congenital diseases account for a significant proportion of perinatal and neonatal mortality in many countries of the region. Birth defects are now considered the leading cause of infant mortality in the United Arab Emirates and the second cause in Bahrain, Kuwait, Oman, and Qatar. Reports from Saudi Arabia indicate that about 25-35% of prenatal deaths in the two hospitals were due to birth defects.
Therefore, this is raising the demand for the genetic testing market.
- Increase in the adoption of next generation sequencing
As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into the molecular underpinnings of individual tumors and specific receptors.
NGS offers advantages in accuracy, sensitivity, and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.
Thus, this is expected to act as a driver for the growth of the genetic testing market.
- Rising disposable income
The expense of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system. In particular, there is a strong association between the complete income level of a country and how much the population of that country spends on health care.
Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the genetic testing market in the forecast period of 2023-2030.
Restraints/Challenges
- High cost of genetic testing
Genetic testing can be expensive and may not be covered by some health insurance plans. The numerous genetic tests differ in costs as per the targeted disease for which it is tested.
- According to Breastcancer.org, the cost of genetic testing for cancer can vary greatly and can be between USD 300 and USD 5,000. How much genetic testing costs can depend on the type of test as well as how complex it is
- Genetic testing can cost anywhere from USD 100 to more than USD 2,000, depending on the test's nature and complexity. If more than one test is required or numerous family members must be tested to acquire a significant result, the expense rises. The cost of neonatal screening varies by state
Thus, the high cost of genetic testing may restrain the market's growth.
- Stringent regulation policy
Regulatory affairs (RA) play a crucial role in the medical devices industry because it is concerned with the healthcare product lifecycle. It serves tactical, strategic, and operational paths and assists in functioning within regulations to expedite the delivery and development of safe as well as effective cancer spit test devices and products to the population worldwide. The role of regulatory affairs is to establish and execute a regulatory strategy.
Many healthcare organizations and government agencies are providing regulatory policies for the launch and approval of cancer spit test devices and products. Approval for the product by regional regulators plays an essential role for the drug development team. The approval assures the company's drug development activities and differentiates the company from the competition.
Post-COVID-19 Impact on the Middle East and Africa Genetic Testing Market
The genetic testing market has been badly affected by COVID-19. Hospital admissions were limited to non-essential treatment, and clinics were temporarily closed during the pandemic. The implementation of social distancing, blocking the population, and limited access to clinics have greatly affected the market. The slowdown in patient flows and referrals also affected the market growth. However, the market will continue to grow in the post-pandemic period due to the relaxation of previously imposed restrictions.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launches, and strategic partnerships to improve the technology and test results involved in the genetic testing market.
Recent Development
- On 10 November 2022, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced UroSuite, a comprehensive suite of genetic risk assessment tests that cover all stages of prostate cancer care. UroSuite includes Myriad's Prolaris Prostate Cancer Test, MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and Precise Tumor Molecular Profile Test. The combination of tests provides an integrated genetic overview and facilitates treatment and selection of clinical trials for patients.
- In September 2022, Illumina, Inc., a world leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq X-Series (NovaSeq X and NovaSeq X Plus). These are new production-scale sequencers that push the boundaries of genomic medicine by enabling faster, more efficient, and more sustainable sequencing. With revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year—2.5 times the performance of previous sequencers—dramatically accelerating genome discovery and clinical insights to understand the disease and ultimately transform patients' lives.
Middle East and Africa Genetic Testing Market Scope
Middle East and Africa genetic testing market is segmented into type, technology, diseases, and end user. The growth amongst these segments will help you analyze and measure growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Diagnostic testing
- Prenatal testing
- New born screening
- Predictive and presymptomatic testing
- Carrier testing
- Other types
On the basis of type, the Middle East and Africa genetic testing market is segmented into diagnostic testing, prenatal testing, new born screening, predictive and presymptomatic testing, carrier testing other types.
TECHNOLOGY
- Polymerase chain reaction
- DNA sequencing (NGS-based testing)
- Whole genome sequencing
- Microarrays
- Fluorescence in situ hybridization (FISH)
- Others
On the basis of technology, the Middle East and Africa genetic testing market is segmented into DNA sequencing, polymerase chain reaction, microarrays, whole genome sequencing, fluorescence in situ hybridization (FISH), and others.
Diseases
- Cancer
- Sickle cell anemia
- Thalassemia
- Rare genetic disorder
- Fragile X Syndrome
- Duchenne muscular dystrophy
- Huntington's disease
- Cystic Fibrosis
- Reproductive genetic testing
- Health & wellness genetic testing
- Others
On the basis of diseases, the Middle East and Africa genetic testing market is segmented into rare Genetic Disorder, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington's disease, fragile X syndrome, reproductive genetic testing, health & wellness genetic testing, and other.
End User
- Hospitals
- Clinics
- Diagnostic centers
- Private clinics
- Laboratory service providers
- Private laboratories
On the basis of end users, the Middle East and Africa genetic testing market is segmented into hospitals, clinics, diagnostic centers, private clinics, laboratory service providers, and private laboratories.
Middle East and Africa Genetic Testing Market Regional Analysis/Insights
The Middle East and Africa genetic testing market is analyzed, and market size information is provided by type, technology, diseases, and end-user.
The countries covered in this market report are South Africa, Saudi Arabia, UAE, Egypt, Israel, the rest of the Middle East and Africa.
In 2023, South Africa is expected to dominate due to the increasing investment in R&D is expected to boost the market growth.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Genetic Testing Market Share Analysis
Le paysage concurrentiel du marché des tests génétiques au Moyen-Orient et en Afrique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et l'ampleur du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise vers le marché des tests génétiques au Moyen-Orient et en Afrique.
Français Certains des principaux acteurs opérant sur le marché des tests génétiques au Moyen-Orient et en Afrique sont Abbott, 23ANDME, Inc., Danaher, Myriad Genetics, Inc., OCP Medical Centre, LLC, Healthchecks360, Bayer AG, BioReference Health, LLC (une filiale d'OPKO Health, Inc.), FREIBURG MEDICAL LABORATORY MIDDLE EAST (LLC), Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Biocartis, Eurofins Scientific, PerkinElmer Inc., ELITechGroup, F. Hoffmann-La Roche Ltd., Illumina, Inc., QIAGEN, BIO-HELIX et PacBio, entre autres.
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure, le Moyen-Orient et l'Afrique par rapport aux régions et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 YEARS CONSIDERED FOR THE STUDY
2.3 CURRENCY AND PRICING
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET APPLICATION COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL’S MODEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 STRATEGIC INITIATIVES:
5 INDUSTRY INSIGHTS
5.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.2 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
5.3 GENETIC TESTS PRICING AND KEY PRICING STRATEGIES
5.3.1 LAUNCH OF NEW TECHNOLOGY GENETIC TESTING KITS
5.3.2 PARTNERSHIPS WITH MARKET PLAYERS
5.3.3 PRENATAL PRICING STRATEGY
5.4 KEY PATIENT ENROLLMENT STRATEGIES
5.4.1 AWARENESS OF THE PUBLIC TOWARDS GENETIC TESTING TECHNOLOGY
5.4.2 GENETIC COUNSELLORS' SCOPE OF PRACTICE
5.4.3 EDUCATION AND COMMUNICATION
6 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: REGULATIONS
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
8.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
8.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYER
8.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
8.2 RESTRAINT
8.2.1 HIGH COST OF GENETIC TESTING
8.2.2 CYBER SECURITY CONCERN IN GENOMICS
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
8.3.2 TECHNOLOGICAL ADVANCEMENTS IN GENETIC TESTING
8.3.3 INCREASING RESEARCH AND DEVELOPMENT
8.3.4 RISING DISPOSABLE INCOME
8.4 CHALLENGES
8.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
8.4.2 STRINGENT REGULATION POLICY
9 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSTIC TESTING
9.3 PRENATAL TESTING
9.3.1 NON-INVASIVE SCREENING
9.3.1.1 BY SCREENING METHOD
9.3.1.1.1 WHOLE GENOME SEQUENCING
9.3.1.1.2 COUNTING OF CFDNA FRAGMENTS
9.3.1.1.3 OTHERS
9.3.1.2 BY CONDITION
9.3.1.2.1 TRISOMY 21
9.3.1.2.2 KLINEFELTER SYNDROME
9.3.1.2.3 JACOBS SYNDROME
9.3.1.2.4 CYSTIC FIBROSIS
9.3.1.2.5 TURNER SYNDROME
9.3.1.2.6 TRISOMY 18
9.3.1.2.7 HEMOPHILIA
9.3.1.2.8 TRISOMY 13
9.3.1.2.9 MICRODELETION SYNDROME
9.3.1.2.10 FETAL GENDER
9.3.1.2.11 OTHERS
9.3.1.3 BY SCREENING TYPE
9.3.1.3.1 CARRIER SEQUENCING
9.3.1.3.2 SEQUENTIAL SEQUENCING
9.3.2 MATERNAL SERUM QUAD SCREENING
9.4 NEW BORN SCREENING
9.4.1 SICKLE CELL DISEASE
9.4.2 CONGENITAL HYPOTHYROIDISM
9.4.3 PHENYLKETONURINA (PKU)
9.4.4 GALACTOSEMIA
9.4.5 MAPLE SYRUP URINE DISEASE
9.4.6 OTHERS
9.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
9.6 CARRIER TESTING
9.6.1 BY TEST TYPE
9.6.1.1 MOLECULAR SCREENING TEST
9.6.1.2 BIOCHEMICAL SCREENING TEST
9.6.2 BY TYPE
9.6.2.1 EXPANDED CARRIER SCREENING
9.6.2.1.1 PREDESIGNED PANEL TESTING
9.6.2.1.2 CUSTOM-MADE PANEL TESTING
9.6.2.2 TARGETED DISEASE CARRIER SCREENING
9.6.3 BY MEDICAL CONDITION
9.6.3.1 HEMATOLOGICAL CONDITIONS
9.6.3.2 PULMONARY CONDITIONS
9.6.3.3 NEUROLOGICAL CONDITIONS
9.6.3.4 OTHER CONDITIONS
9.7 OTHER TYPES
10 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY
10.1 OVERVIEW
10.2 POLYMERASE CHAIN REACTION
10.2.1 REAL-TIME PCR (QPCR)
10.2.2 DIGITAL PCR (DPCR)
10.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
10.2.4 HOT-START PCR
10.2.5 MULTIPLEX PCR
10.2.6 OTHER PCR
10.3 DNA SEQUENCING (NGS-BASED TESTING)
10.3.1 NEXT GENERATION SEQUENCING (NGS)
10.3.2 SANGER SEQUENCING (SINGLE GENE)
10.3.3 OTHER
10.4 WHOLE GENOME SEQUENCING
10.5 MICROARRAYS
10.5.1 DNA MICROARRAYS
10.5.2 PROTEIN MICROARRAYS
10.5.3 OTHER MICROARRAYS
10.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
10.7 OTHERS
11 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY DISEASES
11.1 OVERVIEW
11.2 CANCER
11.2.1 BREAST
11.2.2 COLON
11.2.3 LUNG
11.2.4 PROSTATE
11.2.5 OTHERS
11.3 REPRODUCTIVE GENETIC TESTING
11.4 HEALTH AND WELLNESS GENETIC TESTING
11.5 SICKLE CELL ANEMIA
11.6 THALASSEMIA
11.7 RARE GENETIC DISORDER
11.7.1 TRISOMY 21
11.7.2 MONOSOMY X
11.7.3 TRISOMY 13
11.7.4 MICRODELETION SYNDROME
11.7.5 TRISOMY 18
11.7.6 OTHERS
11.8 FRAGILE X SYNDROME
11.9 DUCHENNE MUSCULAR DYSTROPHY
11.1 HUNTINGTON'S DISEASE
11.11 CYSTIC FIBROSIS
11.12 OTHERS
12 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 DIAGNOSTIC CENTERS
12.5 PRIVATE CLINICS
12.6 LABORATORY SERVICE PROVIDERS
12.7 PRIVATE LABORATORIES
13 SUMMARY WRITE-UP (MIDDLE EAST AND AFRICA)
13.1 OVERVIEW
13.2 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY COUNTRY
13.2.1 SOUTH AFRICA
13.2.2 SAUDI ARABIA
13.2.3 U.A.E.
13.2.4 ISRAEL
13.2.5 EGYPT
13.2.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 BAYER AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 ABBOTT
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 ILLUMINA, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 THERMO FISHER SCIENTIFIC INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 F.HOFFAMANN-LA ROCHE LTD.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 BIOREFERNCE HEALTH INC. (SUBSIDIARY OPKO HEALTH, INC.)
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 ELITECHGROUP
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 23ANDME, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BIOCARTIS
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 BIO-HELIX
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 BIO-RAD LABORATORIES, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 DANAHER
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 EUROFINS SCIENTIFIC
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENTS
16.14 FREIBURG MEDICAL LABORATORY MIDDLE EAST (L.L.C)
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 HEALTHCHECKS360
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 MYRIAD GENETICS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 OCP MEDICAL CENTER L.L.C
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 PACBIO
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENTS
16.19 PERKINELMER ONC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENTS
16.2 QIAGEN
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Liste des tableaux
TABLE 1 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 3 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 4 MIDDLE EAST AND AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 6 MIDDLE EAST AND AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 7 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 9 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 10 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 13 MIDDLE EAST AND AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 14 MIDDLE EAST AND AFRICA NEW BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 17 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 18 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 20 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 21 MIDDLE EAST AND AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 23 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 24 MIDDLE EAST AND AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET , BY DISEASES, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 33 IDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY COUNTRY 2021-2030 (USD MILLION)
TABLE 34 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 35 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 36 SOUTH AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 37 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 38 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 39 SOUTH AFRICA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 40 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 41 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 42 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 43 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 44 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 45 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 46 SOUTH AFRICA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 47 SOUTH AFRICA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 50 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 51 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 53 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 54 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 56 SOUTH AFRICA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 57 SOUTH AFRICA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 58 SOUTH AFRICA GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 59 SOUTH AFRICA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 60 SOUTH AFRICA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 61 SOUTH AFRICA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 62 SOUTH AFRICA GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 63 SOUTH AFRICA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 64 SOUTH AFRICA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 65 SOUTH AFRICA GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 66 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 67 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 68 SAUDI ARABIA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 69 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 71 SAUDI ARABIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 72 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 73 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 74 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 75 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 76 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 77 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 78 SAUDI ARABIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 79 SAUDI ARABIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 80 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 82 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 83 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 85 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 86 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 87 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 88 SAUDI ARABIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 89 SAUDI ARABIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 90 SAUDI ARABIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 SAUDI ARABIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 92 SAUDI ARABIA DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 98 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 100 U.A.E. GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 101 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 103 U.A.E. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 104 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 105 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 106 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 107 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 108 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 109 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 110 U.A.E. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 111 U.A.E. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 112 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 114 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 115 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 117 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 118 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 120 U.A.E. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 121 U.A.E. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 122 U.A.E. GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 123 U.A.E. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 124 U.A.E. DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 125 U.A.E. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 126 U.A.E. GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 127 U.A.E. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 128 U.A.E. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 129 U.A.E. GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 130 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 132 ISRAEL GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 133 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 134 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 135 ISRAEL PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 136 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 137 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 138 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 139 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 140 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 141 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 142 ISRAEL NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 143 ISRAEL NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 146 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (ASP)
TABLE 147 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 149 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 150 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 152 ISRAEL EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 153 ISRAEL CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 160 ISRAEL CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 161 ISRAEL GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 162 EGYPT GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 163 EGYPT GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 164 EGYPT GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 165 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 166 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 167 EGYPT PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 168 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (USD MILLION)
TABLE 169 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (UNITS)
TABLE 170 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2021-2030 (ASP)
TABLE 171 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2021-2030 (USD MILLION)
TABLE 172 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (USD MILLION)
TABLE 173 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (UNITS)
TABLE 174 EGYPT NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2021-2030 (ASP)
TABLE 175 EGYPT NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 177 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 178 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 179 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 180 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 181 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 182 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 183 EGYPT EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 184 EGYPT CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2021-2030 (USD MILLION)
TABLE 185 EGYPT GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 186 EGYPT POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 187 EGYPT DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 188 EGYPT MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 189 EGYPT GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 190 EGYPT RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 191 EGYPT CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2021-2030 (USD MILLION)
TABLE 192 EGYPT GENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 193 REST OF MIDDLE EAST AND AFRICA GENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET:DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET :COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET : DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF GENETIC DISEASES AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 DIGANOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET IN 2023 & 2030
FIGURE 13 EPIDEMIOLOGY
FIGURE 14 INCIDENCE OF ALL GENDER-SOUTH AFRICA AND SAUDI ARABIA
FIGURE 15 INCIDENCE OF ALL GENDER-UAE AND EGYPT
FIGURE 16 INCIDENCE OF ALL GENDER-ISRAEL
FIGURE 17 MORTALITY RATE- SOUTH AFRICA AND SAUDI ARABIA
FIGURE 18 MORTALITY RATE-UAE AND EGYPT
FIGURE 19 MORTALITY RATE-ISRAEL
FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA GENETIC TESTING MARKET
FIGURE 21 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, 2022
FIGURE 22 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 23 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 24 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2022
FIGURE 26 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 27 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 28 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, 2022
FIGURE 30 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, 2023-2030 (USD MILLION)
FIGURE 31 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, CAGR (2023-2030)
FIGURE 32 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, 2022
FIGURE 34 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 35 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 36 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: SNAPSHOT (2022)
FIGURE 38 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY COUNTRY (2022)
FIGURE 39 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: BY TYPE (2023-2030)
FIGURE 42 MIDDLE EAST AND AFRICA GENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
